Announcing 3 New MastDiscs®
Mast Group is excited to announce the launch of three new MASTDISCS® antimicrobial susceptibility test (AST) cartridges: AZA50C, RZF5C, and SUD20C.
These new discs offer advanced AST testing solutions for serious, often life-threatening infections caused by critical pathogens, including Candida species and multidrug-resistant gram-negative bacteria.
These new MASTDISCS® represent the latest developments in antimicrobial susceptibility testing and support optimal treatment decisions in the global fight against antimicrobial resistance (AMR).
RZF5C (Rezafungin 5 µg)
Rezafungin is a second-generation echinocandin, offering an innovative solution for treating Candida infections, which are responsible for a significant number of invasive fungal diseases worldwide. Candidemia, a bloodstream infection caused by Candida species, has a high mortality rate, often exceeding 30%, particularly in immunocompromised patients. Invasive candidiasis affects critically ill patients, and prompt, accurate treatment is vital.
- Use: Candidemia and invasive candidiasis.
- Guidelines: Available for testing under CLSI guidelines only.
SUD20C (Sulbactam 10 µg/ Durlobactam 10 µg)
The combination of Sulbactam and Durlobactam targets Acinetobacter baumannii-calcoaceticus complex, a pathogen associated with hospital-acquired infections and ventilator-associated pneumonia. These infections are notoriously difficult to treat and are a growing global health concern, especially in intensive care units (ICUs). The introduction of SUD20C helps address this growing threat for a pathogen classified as a priority for the development of new antibiotics by the World Health Organization (WHO).
- Use: Hospital-acquired and ventilator-associated pneumonia caused by Acinetobacter baumannii.
- Guidelines: Available for testing under CLSI guidelines only.
AZA50C (Aztreonam 30 µg/ Avibactam 20 µg)
AZA50C combines Aztreonam with Avibactam, forming a potent weapon against multidrug-resistant gram-negative infections, such as complicated intra-abdominal infections (cIAIs), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTIs). These infections are a significant burden on healthcare systems globally. The growing prevalence of extended-spectrum β-lactamase (ESBL)-producing bacteria makes AZA50C a critical tool for clinicians in managing serious infections caused by resistant pathogens.
- Use: Intra-abdominal infections, pneumonia, and complicated urinary tract infections caused by gram-negative organisms.
- Guidelines: Available for testing under both CLSI and EUCAST guidelines.
|
Product Code |
Product Description |
Use |
CLSI/EUCAST |
|
RZF5C |
Rezafungin 5 µg |
Second generation echinocandin for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options |
CLSI Only |
|
SUD20C |
Sulbactam 10 µg/ Durlobactam 10 µg |
B-lactam—B-lactamase inhibitor combination for the treatment of hospital acquired e and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complexs |
CLSI Only |
|
AZA50C |
Aztreonam 30 µg/ Avibactam 20 µg |
β-lactam–β-lactamase inhibitor combination for the treatment of complicated intra-abdominal infection, hospital acquired and ventilator-associated bacterial pneumonia, complicated urinary tract infection, including pyelonephritis caused by susceptible isolates of gram-negative aerobic organisms |
CLSI and EUCAST |
The infections targeted by these new MASTDISCS represent some of the most pressing challenges in global healthcare. Candidemia, ventilator-associated pneumonia, and infections caused by multidrug-resistant gram-negative bacteria are increasingly common in healthcare settings worldwide. The World Health Organization (WHO) has identified antimicrobial resistance (AMR) as one of the top 10 global public health threats, and pathogens like Candida, Acinetobacter, and ESBL-producing bacteria play a significant role in this crisis.
- Candidemia: With an incidence rate ranging from 2 to 10 cases per 100,000 people annually, candidemia is a serious infection, particularly in ICU and immunocompromised patients. It is a leading cause of bloodstream infections in hospitals globally, contributing to high mortality rates.
- Acinetobacter infections: Infections caused by Acinetobacter baumannii have been linked to prolonged hospital stays and high mortality rates in ICUs. The WHO has declared A. baumannii a critical priority pathogen for antibiotic development, underscoring the urgent need for effective diagnostic tools and treatments.
- Multidrug-resistant gram-negative infections: Complicated intra-abdominal infections, hospital-acquired and ventilator-associated pneumonia, and complicated urinary tract infections caused by resistant gram-negative bacteria are increasingly difficult to treat. These infections result in significant morbidity and mortality worldwide, with resistance to standard treatments leading to limited therapeutic options.
By introducing AZA50C, RZF5C, and SUD20C, Mast Group aims to equip healthcare providers with the tools needed to detect and manage these dangerous infections more effectively. Accurate AST testing is essential to ensure that patients receive appropriate antimicrobial therapy, reduce the spread of resistant infections, and improve patient outcomes on a global scale.
Upcoming IVDR Certification
These products are currently available exclusively for the UKCA territories: England, Scotland, and Wales. To understand the IVDR timeline for your territory, please contact your account manager.
For more information on these new products, please contact your local Mast Group representative or visit our website.
References:
WHO list of bacteria for which new antibiotics are urgently needed
WHO list of drug-resistant bacteria most threatening to human health
WHO prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections
https://www.who.int/publications/i/item/WHO-EMP-IAU-2017.12
CDC Data and Statistics on Candidemia
https://www.cdc.gov/candidiasis/data-research/facts-stats/index.html
Clinical Overview of Invasive Candidiasis
https://www.cdc.gov/candidiasis/hcp/clinical-overview/index.html
UKHSA Report: Bloodstream infection due to Candida (and species formerly part of the Candida genus) in England: 2022